SALUBRINAL-DRIVEN ATTENUATION OF MALIGNANT PHENOTYPES OF 4T1 BREAST CANCER CELLS
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Dec 11, 2014
app pub date -
Jun 5, 2014
filing date -
Jun 5, 2013
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
A method is disclosed for the in vivo treatment of a breast cancer tumor utilizing a therapeutically effective amount of an agent that inactivates the Rac1 GTPase and results in a reduction in cancer cell invasion, reduced cancer cell motility, and reduced volume and weight of the tumor. Agents that can be used in this treatment include salubrinal, guanabenz, and combinations thereof. The agents additionally have proven useful in reducing the development of osteoclastogenesis and reducing bone metastasis.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully